Poll: How Much Discretion Should Payers Have Over Biosimilar Coverage?

Article

Coverage policies for biosimilars in the health care industry are the source of much angst.

How extensive should payer coverage of biosimilars be?

All biosimilars and reference products
Just reference products
Just biosimilars
Just the biosimilars and/or reference products the payer wants to cover
Related Videos
Ha Kung Wong, JD.
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Michael Kleinrock
Ian Henshaw
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.